MET and cancer: As, among TKIs, crizotinib somehow targets different proteins, it will be interesting to test in the future whether known inhibitors of c-Met, ALK, and Stat5 have similar sensitizing effects or mechanisms of action against P-gp-overexpressing drug-resistant cancer cells.